/

Società

De

Non verificato

Dermavant Sciences

Di cosa scriviamo

FarmaceuticaIndustriaMedicina - VarieSaluteScienza

3 comunicati stampa

Guarda tutti i comunicati

25/10/2024

Industria

Scienza

Biotecnologia

Farmaceutica

Sanità

Salute

Igiene alimentare

Medicina - Varie

Dermavant Presents ADORING 3 LTE Final Data on Complete Skin Clearance and Treatment-Free Interval for VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as Two Years Old with Atopic Dermatitis at 2024 Fall Clinical Dermatology Conference

Fonte

Dermavant Sciences

Emittente

1.00

0

24/10/2024

Eventi

Industria

Biotecnologia

Farmaceutica

Salute

Dermavant Presents Data on Achievement of No-to-Minimal Itch and Sleep Improvement in Atopic Dermatitis Patients as Young as Two Years Old at American College of Allergy, Asthma and Immunology Annual Meeting

Fonte

Dermavant Sciences

Emittente

1.00

0

25/06/2024

Industria

Scienza

Igiene alimentare

Biotecnologia

Sanità

Farmaceutica

Salute

Pubblico Esercizio/Vendita al dettaglio

Dermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan

Fonte

Dermavant Sciences

Emittente

1.00

0

Seguaci

0

Compatibilità

0